Recent reports surrounding
Thermo Fisher Scientific Inc. (TMO) carry both positive and negative indications for the company's stock. On the acquisition front, numerous global firms, including
Eastern Bank, Conning Inc., Financial Security Advisor Inc., JB Capital LLC, and Davis Rea LTD, among others, have expanded their position in TMO, signaling growing investor confidence. Equally, some such as
Commerzbank, Aberdeen Group, and NBT Bank have sold their TMO shares. TMO's price target has been raised to
$650. Notably, J.P. Morgan initiated the company with a Buy rating. On the financial front, TMO reported an earnings increase and announced a CFO transition. It also secured a
$1 billion vaccine manufacturing pact with Vaxcyte. Nonetheless, the company stock traded down due to concerns over spending cuts. The firm has also announced strategic deals, partnerships, major U.S. expansion moves, and an R&D partnership with AstraZeneca BioVentureHub. Despite mixed reactions in the market, there is a strong opinion that TMO remains a strong option for a long-term investment.
Thermo Fisher Scientific TMO News Analytics from Fri, 18 Apr 2025 07:00:00 GMT to Sat, 11 Oct 2025 11:45:24 GMT -
Rating 3
- Innovation 5
- Information 7
- Rumor -5
